Most adolescents and young adults who were dispensed a GLP-1 receptor agonist in 2023 were female and from the South
Patchett AA, Nargund RP, Tata JR, et al
GLP-1s are not going anywhere pharma manufacturers continue to evolve their GLP-1/GIP product offerings (e.g., Eli Lillys Zepbound is the newest on the market), and the number of addressable indications is increasing (e.g., recent clinical evidence that may merit further FDA approval of GLP-1s for cardio-metabolic, nephrological and neurological indications)
The drug had a half-life of about one week and stronger effects on glycaemia and body weight with mean reductions in HbA 1c of 18 mmol/mol and in body weight of 5.7 kg in the phase-III programme [20]
Like an apple is not junk food, and a Snickers bar is junk food
Literally none of these ingredients have been proven to be as effective as GLP-1 agonists